The company’s platform, the NewStem Software Diagnostic Device, provides information to oncologists regarding the presence of mutations in a patient’s tumor profile that may confer resistance to certain anti-cancer drugs, according to a Dec. 14 press release NovelStem International shared with Becker’s.
MSK Innovation Hub will work together with the company to develop new ways to bring better treatments to cancer patients and help build out and commercialize NovelStem’s platform.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.